Acadian Asset Management LLC Sells 751,458 Shares of Organogenesis $ORGO

Key Points

• Acadian Asset Management LLC reduced its stake in Organogenesis by 24.4%, now holding 2,333,245 shares valued at approximately $10.07 million.
• Organogenesis reported a quarterly earnings miss with an EPS of ($0.09), falling short of analysts' estimates and revenue expectations.
• Analysts are optimistic about Organogenesis, with Cantor Fitzgerald raising its price target from $7.00 to $9.00 and a consensus rating of "Moderate Buy" on the stock.

Acadian Asset Management LLC lowered its holdings in Organogenesis (NASDAQ:ORGO - Free Report) by 24.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,333,245 shares of the company's stock after selling 751,458 shares during the quarter. Acadian Asset Management LLC owned 1.84% of Organogenesis worth $10,067,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Driehaus Capital Management LLC purchased a new stake in Organogenesis during the first quarter valued at $7,756,000. Invesco Ltd. increased its position in Organogenesis by 779.7% during the first quarter. Invesco Ltd. now owns 1,069,252 shares of the company's stock valued at $4,619,000 after acquiring an additional 947,705 shares during the last quarter. Vanguard Group Inc. increased its position in Organogenesis by 23.4% during the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock valued at $19,144,000 after acquiring an additional 841,618 shares during the last quarter. Soleus Capital Management L.P. increased its position in Organogenesis by 5.4% during the fourth quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock valued at $39,952,000 after acquiring an additional 645,000 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Organogenesis by 1,158.6% during the first quarter. SG Americas Securities LLC now owns 525,421 shares of the company's stock valued at $2,270,000 after acquiring an additional 483,675 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. BTIG Research reiterated a "buy" rating on shares of Organogenesis in a research report on Tuesday, July 15th. Cantor Fitzgerald upped their price objective on Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $7.50.

Organogenesis Price Performance

Shares of NASDAQ ORGO traded up $0.05 during mid-day trading on Thursday, reaching $4.67. The company's stock had a trading volume of 196,784 shares, compared to its average volume of 1,365,394. The firm has a market capitalization of $591.80 million, a PE ratio of -33.32 and a beta of 1.75. The stock has a fifty day moving average of $4.73 and a two-hundred day moving average of $4.29. Organogenesis has a 52 week low of $2.61 and a 52 week high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). The business had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%. Organogenesis has set its FY 2025 guidance at EPS. Analysts anticipate that Organogenesis will post -0.07 EPS for the current fiscal year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.